Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Bifidobacterium breve MAK40B22B and Reduced Body Fat Mass

Research synthesisLow evidenceModerate effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across 3 randomized controlled trials, Bifidobacterium breve MAK40B22B (also referred to as B-3) consistently showed moderate beneficial effects on reducing body fat mass, with 2 of 3 studies reporting statistically significant results. The evidence suggests effects are typically observed at 8–12 weeks in adults with pre-obesity or a tendency for obesity. Doses and forms were not consistently reported across studies.

  • Studied populations: Healthy pre-obese adults and adults with a tendency for obesity

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Doses and supplement forms were not reported, limiting the ability to generalize findings to specific products or intake levels.

Generated Jul 12, 2026
3 of 3 papers
Back to top